Evidence for radiological and histopathological prognostic importance of detecting extramural venous invasion in rectal cancer: recommendations for radiology and histopathology reporting

Introduction

Extramural venous invasion (EMVI) is widely regarded as an adverse prognostic feature in rectal cancer. Whilst the effect of venous invasion has been studied for more than seven decades, Talbot’s study from St Mark’s Hospital in 1980 was the first to specify the importance of extramural vs intramural venous invasion and show that it was only invasion of tumour into the extramural veins that had a prognostic effect [1]. However, the current literature is somewhat confusing, which is most probably due to heterogeneity of definitions. We discuss some of the available evidence and offer guidance on the optimal criteria for both histopathological and radiological detection of EMVI within the context of modern management of rectal cancer.

Prevalence

The true prevalence of histopathological EMVI in rectal cancer is difficult to know and hinges on the rigour of macroscopic and microscopic pathological evaluation, and whether ancillary techniques have been used. Reported detection rates have been inconsistent and the incidence ranges from 9 to 61% [1–12]. Some series have shown selection bias towards advanced cases which may affect the true prevalence and result in a high EMVI detection rate [13], whilst others do not differentiate between rectal and colonic tumours. A more recent challenge has been that the increasing use of preoperative radiotherapy has led to an inherent false-negative rate, resulting in under-reporting of venous invasion due to obliteration of normal venous architecture when involved veins are destroyed beyond recognition [14].

Histopathology-based detection

Optimal macroscopic examination

Rectal cancer resection specimens must be appropriately opened, pinned out and fixed in formalin solution for at least 48 h before dissection. Once adequately fixed, the specimen should be cross-sectionally sliced transversely at a thickness of 3–4 mm; these thin slices allow identification of the depth of tumour invasion and status of the circumferential resection margin. In addition, serpiginous outgrowths of tumour extending beyond and at right angles to the muscularis propria may be visible and probably represent a focus of EMVI (Fig. 1). Areas for microscopic examination are then selected with at least four sections of tumour taken targeting areas of greatest interest. Evidence suggests that sections taken perpendicular to the tumour at the area of maximal invasion are most likely to identify EMVI [15]. As many rectal tumours will have undergone neoadjuvant radiotherapy, it may be difficult to identify areas of residual tumour; in this instance a greater number of blocks may be required concentrating on areas of fibrosis in the region of the irradiated tumour.

Optimal microscopic examination

The microscopic identification of EMVI relies upon the identification of tumour cells within an endothelial or smooth muscle-lined space containing red blood cells outside the muscularis propria of the bowel wall as defined in the UK Royal College of Pathologists (RCPath) guidelines for reporting colorectal cancer.

Figure 1 Gross pathology specimen showing tumour with EMVI. Intravascular tumour deposits can be seen as serpigenous extensions of tumour projecting from and at right angles to the muscularis propria (see arrows).
Due to the difficulties associated with tissue sectioning and architectural distortion by tumour or fibrosis, vascular spaces may become difficult to identify on routine haematoxylin and eosin (H&E) staining (Fig. 2). As a result the rate of EMVI with H&E staining has been documented to be as low as 8% [17]; however, the RCPath guidelines suggest that EMVI should be detected in at least 25% of cases of colorectal cancer. There is no guidance as to the expected rate in rectal cancers alone or those treated with neoadjuvant radiotherapy; however, 25% may still be an underestimate for the true prevalence of EMVI using an optimal sampling technique. There is poor agreement, even between specialist gastrointestinal histopathologists, when identifying vascular invasion using H&E [18]. In situations where uncertainty or disagreement exists as to the nature of subserosal tumour deposits, the RCPath guidelines recommend that deeper sections through the tissue block should be performed to attempt to clarify the nature of a lesion; alternatively special histochemical and immunohistochemical stains can be invaluable tools.

**Special stains: histochemical staining**

The elastic lamina within medium-to-large vessels provides a landmark, which can be highlighted by special stains such as orcin and elastin Van Gieson (EVG); the application of these stains has been shown to increase the detection of EMVI from 19.6% to 58% [19]. Staining for the elastic lamina also improves agreement between pathologists from poor to fair [18]. The only significant drawback of these methods is that in selected cases interpretation may be hampered by background staining although this is rare.
Special stains: immunohistochemistry

Immunohistochemical stains using antibodies directed towards endothelial (CD31 and CD34) or smooth muscle (smooth muscle actin) antigens within vessel walls also increase the sensitivity of histopathology-detected EMVI. The potential advantage of these methods is an increased specificity over histochemical staining, although the endothelium may become lost or obscured when a tumour embolus occupies a vessel.

Kingston et al. examined the rate of detection when using H&E, EVG and immunohistochemistry for CD31 and CD34 in 50 cases of colorectal cancer in which vascular invasion had previously not been identified; with the use of special stains they identified vascular invasion in 48% of cases [20]. Although this study did not differentiate between intramural and extramural vascular invasion, it showed that EVG was the most sensitive method; however, in a minority of cases immunochemical staining was still required. An example of these histochemical and immunohistochemical stains in practice is shown in Fig. 3a–e.

MRI-based detection

Optimal technique

High-resolution MRI is accurate in detecting EMVI (mrEMVI) both before and after preoperative therapy. Accurate detection is underpinned by strict adherence to technique and image acquisition as well as a three-dimensional understanding of the vascular anatomy surrounding the rectum. Failure of the latter can confuse venous invasion with nodal disease. Most scanners will provide adequate 3 mm slices; however, optimal technique involves ensuring appropriate an field of view (FOV) (16 × 16 cm) to obtain high-resolution images. Incorrect FOV also results in loss of voxel size and ultimately resolution. Furthermore, the field alignment

Figure 4 (a) MRI showing tumour invasion into the superior rectal vein. Dashed arrow indicates tumour extension. Solid arrow shows signal void in vessel which is surrounded by tumour. (b) MRI showing tumour extending into the middle rectal vein. The dashed arrow shows signal void (black) shown in the middle rectal vein; the solid arrow shows tumour extension beyond the muscularis. (c) MRI showing tumour in the inferior rectal vein. There is signal void which could be followed on sequential images confirming this was the inferior rectal vein.
must be perpendicular to the long axis of the rectum or vessels can be missed.

**Characteristic radiological features of EMVI**

Veins around the rectum are recognized on T2-weighted images as serpiginous or tortuous linear structures which appear black due to the signal void of blood. The larger ‘named’ vessels such as the superior and middle rectal veins appear with anatomical consistency, which helps in confident identification. Detection of mrEMVI relies on the observation of intermediate tumour signal disrupting the normal configuration of the vessel resulting in irregular expansion of the vein, loss of the signal void and intermediate signal intensity which may or may not be contiguous with the main tumour in the rectal wall [21]. Smaller venules can be seen perforating the normal outer rectal wall and produce a low to intermediate signal intensity in tubular structures on T2-weighted images — these are normal vessels and should not be confused with mrEMVI [22]. Venous invasion into these smaller venules can be recognized by their expansion and irregularity adjacent to the tumour due to contiguous tumour extension (Fig. 4a–c).

**Early studies showing correlation with histopathology**

The first study to demonstrate the accuracy of MRI in identifying the EMVI as a prognostic feature of rectal cancer involved 98 patients with biopsy-proven rectal cancer [23]. The prognostic significance of mrEMVI has further been documented in a study by Smith et al. [24]. They offered a scoring system based on previous experience which identified particular morphological and signal characteristics. Recurrence-free survival at 3 years was compared between MRI and histopathology-detected EMVI and was reported as 35% and 34%, respectively. Recurrence-free survival when EMVI was not present was 73.8% and 74.1% respectively. A further study using similar grading criteria reported mrEMVI in 42% of patients undergoing primary surgery for rectal cancer. An mrEMVI score of 3–4 had 100% sensitivity and 89% specificity in identifying EMVI involving veins greater than 3 mm in diameter [25].

**The potential of mrEMVI as an imaging biomarker**

The prognostic effect of traditional adverse features has not been prospectively validated in patients who have undergone preoperative therapy. Perhaps those features which we previously understood as having a significant bearing on survival outcomes may not be as important following chemoradiotherapy (CRT) providing optimal surgery has taken place – such as nodal disease [26].

MRI is accurate in identifying EMVI following chemoradiation providing the same diagnostic standard is used [27,28]. Indeed, a comparison between the outcomes of patients with mrEMVI and pathology-detected EMVI showed that, not only is it associated with poor disease-free survival when either technique is used, but MRI identified more cases of EMVI than pathology following CRT [29]. Further, a recent study involving Stage II and Stage III patients who had undergone preoperative long-course CRT showed that evidence of EMVI led to significantly worse disease recurrence and in fact Stage II tumours with EMVI had similar outcomes to Stage III tumours [30]. mrEMVI has also been shown to be a potential imaging biomarker following neoadjuvant CRT. EMVI can be graded following CRT using a regression grading score based on the degree of radiological evidence of fibrosis shown and this can be linked to survival outcomes. Patients who demonstrated fibrosis of more than 50% in EMVI had a 3-year disease-free survival of 87.9%. Where there was less than 50% fibrosis disease-free survival was 45.8%. Fibrosis of less than 50% had a hazard ratio of 5.75 for disease recurrence [31].

**Conclusion**

There is now substantial evidence suggesting that EMVI is an adverse prognostic feature in rectal cancer, including in cases treated with neoadjuvant therapy. Whilst special stains undoubtedly increase the reporting rates, H&E staining unfortunately remains the gold standard for most institutions. The use of special stains will improve detection rates particularly following CRT and must surely now be considered as routine in addition to meticulous technique.

Furthermore, MRI can identify EMVI at the same rate as histopathology and predicts the same outcome. Using the radiological criteria described above will allow for more consistent reporting of EMVI in the preoperative setting. Multidisciplinary teams are urged to regularly audit the reporting rates of EMVI using both MRI and histopathology to ensure good concordance.

**Acknowledgement**

NIHR BRC Programme Grant.

**Conflicts of interests**

None.
Author contributions

All authors contributed equally to analysis and writing of the paper. Conception was between Professor Brown and Mr Chand. Image collection was equally done by all authors.

M. Chand*, T. Palmer†, L. Blomqvist‡, I. Nagtegaal§, N. West¶ and G. Brown**

*Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK; †Imperial College London, Exhibition Road, London, UK; §Karolinska University Hospital, Karolinska, Sweden; ¶Leeds University Hospital, Leeds, UK and **Department of Radiology, Royal Marsden Hospital, Sutton, UK

E-mail: Manish.chand@rmh.nhs.uk

References

28 Yu SK, Tait D, Chau I, Brown G. MRI predictive factors for tumor response in rectal cancer following neoadjuvant

